HER2 and HER3 — Drug Target

All drugs that target HER2 and HER3 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bispecific monoclonal antibody

Phase 3 pipeline (1)

• KN026 · Shanghai JMT-Bio Inc. · Bispecific monoclonal antibody · Oncology
  KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells.